Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target

Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target

Abstract Sarcomas harboring EWSR1-NFATc2 fusions have historically been categorized and treated as Ewing sarcoma. Emerging evidence suggests unique molecular characteristics and chemotherapy sensitivities in EWSR1-NFATc2 fusion positive sarcomas. Comprehensive genomic profiles of 1024 EWSR1 fusion p...

Full description

Bibliographic Details
Main Authors: Nathan D. Seligson, Richard D. Maradiaga, Colin M. Stets, Howard M. Katzenstein, Sherri Z. Millis, Alan Rogers, John L. Hays, James L. Chen
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-021-00177-0

Internet

https://doi.org/10.1038/s41698-021-00177-0

Similar Items